For 4QFY2017, Sun Pharma posted tepid numbers. For the quarter, the sales came in at `6,825cr v/s. `7,600cr expected, registering a yoy dip of 7.9%. India sales at `1,916cr, were up by 10% as compared to 4QFY2016, US finished dosage sales at US$381mn down by 34% vis-à-vis 4QFY2016. On the OPM front, the gross margins came in at 67.8% v/s. 80.4% in 4QFY2016, which lead the EBDITA margins to come in at 18.1% (v/s. 31.1% expected) v/s. 31.0% in 4QFY2016. Despite the sharp dip in margins, the higher other income at `536cr v/s. `185cr in 4QFY2016, lead the Adj. net profit to come in at `1,385cr v/s. `1,433cr expected, a yoy dip of 19.2%. We maintain our Buy.
Download Full Report View Full Report in BrowserPlease Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...